Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-03-14 Annual Report
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Samil Pharmaceutical, which is the Korean equivalent of an Annual Report (10-K). It includes detailed financial statements, management discussion and analysis, and corporate governance information for the fiscal year 2024. Although the document contains a 'Correction Report' (정정 신고) header at the beginning, this is a standard practice for filing amendments to the primary Annual Report in the Korean regulatory system. The document contains comprehensive financial data and is not merely an announcement or a certification. FY 2024
2025-03-14 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, profit/loss) for the fiscal year ending 2024-12-31. While it contains financial data, it is a formal notification of the audit report's completion and submission to the regulator (KRX), rather than the full Annual Report (10-K) or a standalone audit report document. According to the 'Menu vs Meal' rule, this is a regulatory announcement regarding the filing of audit results, which falls under the Audit Report/Information category (AR) as it specifically details the audit opinion and auditor information. FY 2024
2025-03-13 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Samil Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a full annual financial disclosure, not an announcement or a summary, fitting the definition of an Audit Report (AR). FY 2024
2025-03-13 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Samil Pharmaceutical. It contains the meeting agenda, details on electronic voting, and management's reference materials (including financial statements and board activity reports) required for shareholders to make informed decisions. This is a standard proxy solicitation document sent to shareholders prior to the AGM.
2025-03-07 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains information regarding the solicitation of proxies for a shareholder meeting, including the purpose of the meeting, voting methods (electronic/written), and details about the company's financial status as reference material for shareholders. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-07 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Samil Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as board activities and financial statements (balance sheet, income statement) for the 72nd fiscal year. This type of document is standard for providing shareholders with the necessary information to vote on company matters, which falls under the Proxy Solicitation & Information Statement category.
2025-03-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.